))
Resistance Mechanisms in EGFR+ mNSCLC
Manage episode 439565872 series 3599769
Indhold leveret af OntadaLearn. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af OntadaLearn eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Welcome to episode two of three where Dr. John Hamack from MD Anderson Cancer Center and Dr. Millie Doss from Stanford University discuss the latest advancements and ongoing challenges in treating locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer (NSCLC).
Explore the unmet needs in first-line therapy, the variety of resistance mechanisms, and the evolving landscape of treatment strategies. This educational opportunity is brought to you by Johnson & Johnson.
5 episoder
Del
